Immunotherapy before surgery shrinks lung tumors in Early-Stage trial
NCT ID NCT03158129
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested giving immunotherapy drugs (nivolumab alone or with ipilimumab) or immunotherapy plus chemotherapy before surgery for people with early-stage non-small cell lung cancer (stages I to IIIA). The goal was to see if these treatments could shrink or eliminate the tumor before surgical removal. The trial enrolled 101 participants and measured how many had a major or complete response in the tumor tissue after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States